C-Bridge Capital
VC Fund
Shanghai, China
C-Bridge Capital is a VC fund in Shanghai focused on Medical and Health Care. Cambridge Capital is a private equity fund focused on investing in the health care industry. It is principally engaged in the development of advanced and M & A investments, covering all major health areas such as medicine, medical equipment and medical services. Over the past few years, Cambridge Capital has successfully completed investmentprojects covering a number of medical and health segments such as biopharmaceuticals, drug distribution, molecular diagnostics and medical devices.Cambridge Capital is designed to accelerate the development and marketization of modern medical and medical technology through the use of capital to improve the health of the whole people and benefit mankind.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries C-Bridge Capital invests in
Stages C-Bridge Capital invests in
Countries C-Bridge Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Investment Focus
Industry
- Medical 3 (75%)
- Health Care 2 (50%)
- Biotechnology 2 (50%)
- Biopharma 1 (25%)
- Life Science 1 (25%)
Stage
- Angel 1 (25%)
- Series B 1 (25%)
- Venture - Series Unknown 1 (25%)
Country
- China 2 (50%)
- United States 1 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ian Woo
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Jason Brown
Managing Director
|
Managing Director | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Leo Summit
|
Leo Summit is positioned as a provider of life science laboratory automation solutions. It provides reliable and flexible solutions for the biomedical industry, driven by the demand for automated intelligent technology in clinical medicine and drug R&D industries, and relies on artificial intelligence and motion control technology. Providesystematic intelligent products and solutions for R&D firms, AI pharmaceuticals, and CRO firms in the fields of new medications, synthetic biology, and single-cell sequencing. | Angel / Dec 05, 2022 | |
Yaneng Biotechnology
|
Yaneng Biotechnology produces a gene diagnostic chip technology platform. They provide cervical cancer screening and hereditary disease diagnostics, such as pre pregnancy and prenatal diagnosis and screening tests, and automatic nucleic acid extractor. They also provide resarch and development services. | Venture - Series Unknown / Apr 29, 2022 | |
Ascletis
|
Ascletis is a joint venture between U.S. and Chinese entrepreneurs aimed at building a global specialty therapeutics business dedicated to discovering and developing important new treatments for cancer and infectious diseases. Ascletis leverages U.S./European innovation and pharmaceutical/biotech strategic experience and China'scapital efficiency with a goal of establishing in the near term a sustainable business and accelerated revenues through the in-licensing, late-stage clinical development, and commercialization of new medicines for the growing Chinese pharmaceutical marketplace. At the same time, the company is building long-term value through the discovery, demonstration of clinical proof-of-concept, and global partnering of novel therapeutics for life-threatening diseases. | $100M / Series B / Jan 03, 2017 | |
|
Ascletis
|
Ascletis is a joint venture between U.S. and Chinese entrepreneurs aimed at building a global specialty therapeutics business dedicated to discovering and developing important new treatments for cancer and infectious diseases. Ascletis leverages U.S./European innovation and pharmaceutical/biotech strategic experience and China'scapital efficiency with a goal of establishing in the near term a sustainable business and accelerated revenues through the in-licensing, late-stage clinical development, and commercialization of new medicines for the growing Chinese pharmaceutical marketplace. At the same time, the company is building long-term value through the discovery, demonstration of clinical proof-of-concept, and global partnering of novel therapeutics for life-threatening diseases. | $35M / Series B / Sep 02, 2015 |
Co-Investors
Focus Media
1 deal together
Huagai Capital
1 deal together
Pavillion Capital
1 deal together
Tasly Pharmaceutical
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does C-Bridge Capital invest in?
C-Bridge Capital invests primarily in Medical, Health Care and Biotechnology startups, most often at Angel and Series B stage. Most of the 4 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact C-Bridge Capital?
Public channels for C-Bridge Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at C-Bridge Capital?
The team at C-Bridge Capital includes Ian Woo (Managing Director) and Jason Brown (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
